NCT01316263

A Study of Olaratumab (IMC-3G3) in Previously Treated Participants With Unresectable and/or Metastatic Gastrointestinal Stromal Tumors

A Phase 2 Study of a Human Anti-PDGFRα Monoclonal Antibody (IMC-3G3) in Previously Treated Patients With Unresectable and/or Metastatic Gastrointestinal Stromal Tumors (GIST)

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 21 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the tumor response of stable disease (SD), partial response (PR), or complete response (CR) \[according to Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST v1.1 criteria)\] at 12 weeks in participants with Gastrointestinal Stromal Tumors (GIST) harboring platelet-derived growth factor receptor alpha (PDGFRα) mutations and patients with GIST not harboring PDGFRα mutations.

Conditions

• Gastrointestinal Stromal Tumor (GIST)

Interventions

Type	Name	Description
BIOLOGICAL	Olaratumab	Administered IV

Timeline

• Start date: 2011-08-01
• Primary completion: 2012-05-01
• Completion: 2012-11-01
• First posted: 2011-03-16
• Last updated: 2017-03-09
• Results posted: 2017-01-16

Locations

13 sites across 6 countries: United States, Belgium, Germany, Netherlands, Poland, Spain